Cargando…

Urothelial carcinoma with an NRF1-BRAF rearrangement and response to targeted therapy

Although BRAF mutations are commonly identified in many solid tumors and the response of BRAF p.V600E-positive tumors to targeted therapy is well documented, BRAF rearrangements are less frequent and are predominantly found in low-grade glioma, melanoma, lung, colorectal, and thyroid carcinoma. Prec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacson, Alexandra L., Guseva, Natalya V., Bossler, Aaron D., Ma, Deqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2019
Materias:	Rapid Cancer Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549557/ https://www.ncbi.nlm.nih.gov/pubmed/31010895 http://dx.doi.org/10.1101/mcs.a003848

Ejemplares similares

BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior
por: Jones, Karra A., et al.
Publicado: (2019)

Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
por: Wrzeszczynski, Kazimierz O., et al.
Publicado: (2019)

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma
por: Hsiao, Susan J., et al.
Publicado: (2017)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
por: Sompallae, Ramakrishna R., et al.
Publicado: (2023)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Rearranged Epstein‐Barr Virus Genomes and Clonal Origin in Nasopharyngeal Carcinoma
por: Shimakage, Misuzu, et al.
Publicado: (1989)

Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma
por: Miller, Katherine E., et al.
Publicado: (2018)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21)
por: Burlet, Bénédicte, et al.
Publicado: (2021)

Low Frequency of Rearrangements of the ret and trk Proto‐oncogenes in Japanese Thyroid Papillary Carcinomas
por: Wajjwalku, Worawidh, et al.
Publicado: (1992)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma
por: Pagan, Carlos, et al.
Publicado: (2019)

Diffuse midline glioma with novel, potentially targetable, FGFR2–VPS35 fusion
por: Zanazzi, George, et al.
Publicado: (2020)

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
por: Van Cutsem, Eric, et al.
Publicado: (2019)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
por: Hauschild, Axel, et al.
Publicado: (2018)

Detection of Productively Rearranged TcR-α V–J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells
por: Gill, Thomas R., et al.
Publicado: (2016)

Detection of PML/Retinoic Acid Receptor α Gene Rearrangements by Polymerase Chain Reaction Using Genomic DNA in Patients with Acute Promyelocytic Leukemia
por: Tashiro, Satoshi, et al.
Publicado: (1993)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma
por: Nishimura, Goshi, et al.
Publicado: (2000)

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
por: Tabernero, Josep, et al.
Publicado: (2021)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

NRF2 participates in the suppressive tumor immune microenvironment of KRAS/KEAP1 co-mutant non-small cell lung cancer by inhibiting the STING pathway
por: Xiaodan, Sun, et al.
Publicado: (2022)

Immunogenomic classification of lung squamous cell carcinoma characterizes tumor immune microenvironment and predicts cancer therapy
por: Fu, Denggang, et al.
Publicado: (2023)

FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia
por: Ballester, Leomar Y., et al.
Publicado: (2018)

A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense-mediated mRNA decay
por: Krempely, Kate, et al.
Publicado: (2018)

Germline BRCA2 mutations detected in pediatric sequencing studies impact parents’ evaluation and care
por: Walsh, Michael F., et al.
Publicado: (2017)

A case of KMT2A–SEPT9 fusion–associated acute megakaryoblastic leukemia
por: Forlenza, Christopher J., et al.
Publicado: (2018)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma
por: Zhong, Yiming, et al.
Publicado: (2020)

Biallelic loss of GNAS in a patient with pediatric medulloblastoma
por: Tokita, Mari J., et al.
Publicado: (2019)

A novel TP53 tandem duplication in a child with Li–Fraumeni syndrome
por: Xu, Feng, et al.
Publicado: (2022)

Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy
por: Smith, Stephen M., et al.
Publicado: (2022)

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022)

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
por: Ross, Jeffrey S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mjm8ghk1b785imdkublpp37cau